Exceptional clinical coverage

ARUP’s tests include antibodies with significant clinical impact that cover an estimated 95–99% of disease cases.

Excellent turnaround time

Results of our panel tests are reported within three to 10 days. Results of smaller, phenotype-specific panels and standalone tests may be reported in even less time.

Improved diagnostic yield with phenotype-specific panels

New antibodies are frequently discovered, and panel tests may become more expensive as these antibodies are added. ARUP's targeted panels include only the antibodies associated with particular clinical phenotypes to efficiently maximize diagnostic yield.

Broad-coverage panel testing

ARUP’s broad panel tests include a large number of antineural antibodies. This testing can be used to evaluate unexplained, subacute-onset neurologic diseases, including encephalitis, in the presence or absence of malignancy.

Single antibody testing available

ARUP also offers standalone testing for single antibodies, which eliminates the unnecessary ordering of larger panels.